港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

285.400

-3.600-1.25%

成交量：81.19萬

成交額：2.33億

市值：647.86億

市盈率：-222.72

高：294.000

開：285.000

低：275.000

收：289.000

資料載入中...

總覽公司新聞公告

科倫博泰生物-B01月23日主力資金流出277萬元連續3日減倉

科倫博泰生物簽署多個結構性存款協議金額超4億元

科倫博泰生物(06990.HK)認購銀行結構性存款

阿斯达克财经

科倫博泰生物-B認購結構性存款

格隆汇资讯

科倫博泰生物-B盤中異動臨近收盤股價大跌5.19%報159.000港元

科倫博泰生物(06990.HK)SKB445新藥臨牀試驗申請獲批准

阿斯达克财经

科倫博泰生物(06990.HK)抗PD-L1塔戈利單抗獲上市批准

阿斯达克财经

科倫博泰生物-B新藥抗PD-L1塔戈利單抗獲批上市

科倫博泰生物獲SKB445新藥臨牀試驗通知書

科倫博泰生物-B(06990)：抗PD-L1塔戈利單抗獲國家藥監局批准上市

科倫博泰生物-B(06990)：SKB445新藥臨牀試驗申請獲國家藥品監督管理局批准

《大行》高盛微升科倫博泰(06990.HK)目標價至226.56元管理層對中國商業化啓動充滿信心

阿斯达克财经

科倫博泰生物-B01月17日主力資金流入41萬元連續3日加倉

科倫博泰生物-B盤中異動下午盤急速上漲5.13%報168.000港元

【券商聚焦】交銀國際指創新藥企業延續出海熱潮看好板塊仍有較大修復空間

【港股異動 | 科倫博泰生物-B(06990.HK)現跌超4% 】科倫博泰生物-B(06990.HK)現跌超4%，截至發稿，跌3.94%，報163.2港元，成交額1546.06萬港元。

港股異動 | 科倫博泰生物-B(06990)現跌超4% TSLP單抗達成約10億美元海外合作機構小幅下調公司目標價

科倫博泰生物-B(6990.HK)：首款TROP2 ADC獲批上市邁入商業化新徵程

科倫博泰生物-B01月13日主力資金流入6萬元連續3日加倉

【券商聚焦】招銀國際削科倫博泰(06990)目標價6.4% 惟看好SKB264在今年8-10億元人民幣的銷售目標

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2814297530580563,"marketStatus":"復活節星期一休市","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2814297530580563,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.28143,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.39","psRate":"31.48","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2814297530580563,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2814297530580563,"open":285,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505065003","title":"科倫博泰生物-B01月23日主力資金流出277萬元 連續3日減倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2505065003","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505065003?lang=zh_tw&edition=fundamental","pubTime":"2025-01-23 16:15","pubTimestamp":1737620140,"startTime":"0","endTime":"0","summary":"01月23日, 科伦博泰生物-B股价涨2.07%，报收163.00元，成交金额2941万元，换手率0.14%，振幅5.01%，量比0.96。科伦博泰生物-B今日主力资金净流出277万元，连续3日净流出，上一交易日主力净流出159万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为72.73%，平均跌幅为2.40%。该股近5个交易日上涨2.00%，主力资金累计净流出380万元；近20日主力资金累计净流出1184万元，其中净流出天数为8日。该股主力净额占比0.01%，港股市场排名2471/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123161601abb59542&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123161601abb59542&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2505760651","title":"科倫博泰生物簽署多個結構性存款協議 金額超4億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505760651","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505760651?lang=zh_tw&edition=fundamental","pubTime":"2025-01-22 14:42","pubTimestamp":1737528174,"startTime":"0","endTime":"0","summary":"财中社1月22日电科伦博泰生物-B（06990）发布公告，近日公司与中信银行、浙商银行及招商银行签订了多个结构性存款协议。具体而言，公司同意向中信银行认购本金为5000万元的结构性存款，以及向浙商银行认购两笔各为1亿元的结构性存款。此外，公司还与招商银行签订了本金为2亿元的结构性存款协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501223304703877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2505737082","title":"科倫博泰生物(06990.HK)認購銀行結構性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2505737082","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505737082?lang=zh_tw&edition=fundamental","pubTime":"2025-01-22 08:26","pubTimestamp":1737505560,"startTime":"0","endTime":"0","summary":"科伦博泰生物(06990.HK) 公布，认购中信银行(00998.HK) 本金额为5,000万元人民币(下同)的结构性存款。目前，公司向中信银行购买的理财产品的未到期本金总额为3亿元。公司另向浙商银行(02016.HK) 认购两笔结构性存款，每笔本金额为1亿元。目前，公司存置于浙商银行的结构性存款的未偿还本金总额为3.5亿元。此外，公司向招商银行(03968.HK) 认购一笔结构性存款，本金额为2亿元。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-21 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1412270/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["161121","06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2505319677","title":"科倫博泰生物-B認購結構性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2505319677","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505319677?lang=zh_tw&edition=fundamental","pubTime":"2025-01-22 07:41","pubTimestamp":1737502915,"startTime":"0","endTime":"0","summary":"格隆汇1月22日丨科伦博泰生物-B发布公告，2025年1月21日，公司订立中信银行结构性存款协议III，据此，公司同意向中信银行认购本金额为人民币5000万元的结构性存款。于本公告日期，存置于浙商银行的结构性存款的未偿还本金总额为人民币3.50亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122074201960c1b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122074201960c1b47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2505214875","title":"科倫博泰生物-B盤中異動 臨近收盤股價大跌5.19%報159.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505214875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505214875?lang=zh_tw&edition=fundamental","pubTime":"2025-01-21 15:37","pubTimestamp":1737445069,"startTime":"0","endTime":"0","summary":"2025年01月21日临近收盘15时37分，科伦博泰生物-B股票出现波动，股价急速下挫5.19%。截至发稿，该股报159.000港元/股，成交量21.8万股，换手率0.17%，振幅5.90%。资金方面，该股资金流入1758.35万港元，流出1492.15万港元。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.12%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121153749abb2d00e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121153749abb2d00e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2505238683","title":"科倫博泰生物(06990.HK)SKB445新藥臨牀試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2505238683","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505238683?lang=zh_tw&edition=fundamental","pubTime":"2025-01-21 00:42","pubTimestamp":1737391320,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，创新药物SKB445的新药临床试验申请已获国家药品监督管理局药品审评中心批准。SKB445是一款由公司针对靶点生物学特点，利用OptiDC平台技术研发的具有自主知识产权的新型ADC药物。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-20 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1411876/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1141","LU0196878994.USD","BK1161","06990","BK1576","BK1583"],"gpt_icon":0},{"id":"2505238501","title":"科倫博泰生物(06990.HK)抗PD-L1塔戈利單抗獲上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2505238501","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505238501?lang=zh_tw&edition=fundamental","pubTime":"2025-01-21 00:42","pubTimestamp":1737391320,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，公司联合顺铂和吉西他滨用于一线治疗复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体塔戈利单抗(科泰莱)已获中国国家药品监督管理局批准于中国上市。这是塔戈利单抗获批的第二项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-20 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1411877/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2504040445","title":"科倫博泰生物-B新藥抗PD-L1塔戈利單抗獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504040445","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504040445?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 20:21","pubTimestamp":1737375681,"startTime":"0","endTime":"0","summary":"财中社1月20日电科伦博泰生物-B（06990）发布公告，公司的抗PD-L1单抗塔戈利单抗（前称KL-A167）已获得中国国家药品监督管理局批准上市。该药物用于一线治疗复发或转移性鼻咽癌患者，联合顺铂和吉西他滨的治疗方案在有效性和安全性方面表现优异。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501203302386677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169589451.USD","BK1161","BK4023","LU0196878994.USD","LU1169590202.USD","06990","PD"],"gpt_icon":0},{"id":"2504402224","title":"科倫博泰生物獲SKB445新藥臨牀試驗通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2504402224","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504402224?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 20:21","pubTimestamp":1737375660,"startTime":"0","endTime":"0","summary":"财中社1月20日电科伦博泰生物-B（06990）发布公告，宣布公司已于2025年1月20日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB445新药临床试验申请的临床试验通知书。SKB445是一款由公司针对靶点生物学特征，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，临床前研究显示出良好的疗效和安全性，计划用于治疗晚期实体瘤。公告中提到，SKB445的最终成功开发及商业化仍存在不确定性，公司提醒股东及潜在投资者在买卖公司证券时需谨慎行事。（文章来源：财中社）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120202920960a48fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120202920960a48fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1576","BK1161","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2504401512","title":"科倫博泰生物-B(06990)：抗PD-L1塔戈利單抗獲國家藥監局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504401512","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504401512?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 20:09","pubTimestamp":1737374944,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司联合顺铂和吉西他滨用于一线治疗复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1的创新人源化单克隆抗体塔戈利单抗(科泰莱)已获中国国家药品监督管理局批准于中国上市。本次获批主要基于一项评价塔戈利单抗联合顺铂和吉西他滨对照安慰剂联合顺铂和吉西他滨治疗复发或转移性鼻咽癌的有效性和安全性的随机、双盲、安慰剂对照、多中心III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1240635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","06990","BK1161","LU0196878994.USD","PD","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2504401834","title":"科倫博泰生物-B(06990)：SKB445新藥臨牀試驗申請獲國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2504401834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504401834?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 20:05","pubTimestamp":1737374714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，该公司董事会欣然宣布，公司已于2025年1月20日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB445新药临床试验申请的临床试验通知书。SKB445是一款由公司针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1240629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","03347","BK1141","06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2504449171","title":"《大行》高盛微升科倫博泰(06990.HK)目標價至226.56元  管理層對中國商業化啓動充滿信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449171","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504449171?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 10:53","pubTimestamp":1737341580,"startTime":"0","endTime":"0","summary":"高盛发表报告，调整对科伦博泰生物-B目标价，由226.32元调整至226.52元，维持“买入”评级。管理层重申对今年表现强劲有信心，指引为全年销售8亿至10亿元人民币。该行下调(收窄)对公司2024年至2026年每股亏损预测，由0.5元至4.3元人民币，降至0.1元至2.6元人民币，反映SKB264药物今年销售指引，调整销售提速趋势预测，以及近期乐品开发进展。沽空资料截至 2025-01-17 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1411667&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2504317981","title":"科倫博泰生物-B01月17日主力資金流入41萬元 連續3日加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2504317981","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504317981?lang=zh_tw&edition=fundamental","pubTime":"2025-01-17 16:16","pubTimestamp":1737101790,"startTime":"0","endTime":"0","summary":"01月17日, 科伦博泰生物-B股价涨1.75%，报收162.60元，成交金额3600万元，换手率0.17%，振幅7.20%，量比1.33。科伦博泰生物-B今日主力资金净流入41万元，连续3日净流入，上一交易日主力净流入120万元，今日环比减少65.83%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为53.85%，平均涨幅为4.78%。该股近5个交易日下跌2.48%，主力资金累计净流出483万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出838万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117161806a22551c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117161806a22551c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2504013179","title":"科倫博泰生物-B盤中異動 下午盤急速上漲5.13%報168.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504013179","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504013179?lang=zh_tw&edition=fundamental","pubTime":"2025-01-17 13:26","pubTimestamp":1737091583,"startTime":"0","endTime":"0","summary":"2025年01月17日下午盘13时26分，科伦博泰生物-B股票出现波动，股价急速拉升5.13%。截至发稿，该股报168.000港元/股，成交量12.3839万股，换手率0.09%，振幅7.20%。资金方面，该股资金流入1209.91万港元，流出372.272万港元。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，北海康成-B、华康生物医学、帝王国际投资涨幅较大，振幅较大的相关个股有北海康成-B、华康生物医学、创胜集团-B，振幅分别为53.91%、21.37%、12.90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501171326249606e622&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501171326249606e622&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2503898877","title":"【券商聚焦】交銀國際指創新藥企業延續出海熱潮 看好板塊仍有較大修復空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2503898877","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503898877?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 09:14","pubTimestamp":1736990079,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，新年中国创新药企业延续出海热潮，信达生物 、先声药业、康诺亚、科伦博泰/和铂医药、映恩生物等企业成功与MNC大药企或通过NewCo形式将创新药资产授权出海，该行认为出海仍是2025年创新药板块最大的看点之一，更多重磅交易值得期待。结合此前各类药械集采持续为创新品种医保支付创造资金空间、后续财政和医保/商保利好政策继续出台、估值仍处历史底部，该行认为板块仍有较大修复空间。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1951536","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU2488822045.USD","BK1191","BK1147","01801","LU1969619763.USD","LU0196878994.USD","BK1587","01952","BK1161","02142","02096","02162","BK1574","LU2328871848.SGD","IE00BPRC5H50.USD","BK1583","LU0348783233.USD","BK1589","IE00B543WZ88.USD","LU1720050803.USD","159992","03329","IE00B5MMRT66.SGD","06978","LU0348784397.USD","LU0417516571.SGD","09926","06990"],"gpt_icon":0},{"id":"2503501666","title":"【港股異動 | 科倫博泰生物-B(06990.HK)現跌超4% 】科倫博泰生物-B(06990.HK)現跌超4%，截至發稿，跌3.94%，報163.2港元，成交額1546.06萬港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503501666","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503501666?lang=zh_tw&edition=fundamental","pubTime":"2025-01-15 13:54","pubTimestamp":1736920471,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990.HK)现跌超4%，截至发稿，跌3.94%，报163.2港元，成交额1546.06万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15135447470293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2503665026","title":"港股異動 | 科倫博泰生物-B(06990)現跌超4% TSLP單抗達成約10億美元海外合作 機構小幅下調公司目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2503665026","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503665026?lang=zh_tw&edition=fundamental","pubTime":"2025-01-15 13:50","pubTimestamp":1736920257,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B现跌超4%，截至发稿，跌3.94%，报163.2港元，成交额1546.06万港元。消息面上，SKB378是科伦博泰与和铂医药共同开发的TSLP单抗，现已对外授权给Windward公司。交易价值最高可达9.7亿美元，含4,500万美元的首付款和近期付款，将以现金和Windward母公司股权支付，科伦博泰与和铂医药将平分款项。招银国际发布研报称，维持科伦博泰“买入”评级。同时将公司目标价由243.38港元降至227.88港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1237867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TSLP","06990"],"gpt_icon":0},{"id":"2503669024","title":"科倫博泰生物-B(6990.HK)：首款TROP2 ADC獲批上市 邁入商業化新徵程","url":"https://stock-news.laohu8.com/highlight/detail?id=2503669024","media":"华西证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503669024?lang=zh_tw&edition=fundamental","pubTime":"2025-01-15 00:00","pubTimestamp":1736870400,"startTime":"0","endTime":"0","summary":"芦康沙妥珠单抗作为国内首款上市TROP2ADC 自研产品，截至目前已围绕乳腺癌、肺癌两大领域布局多项适应症，其中：国内单药后线治疗三阴性乳腺癌已获批，单药2/3L 治疗EGFRmt NSCLC 已提交上市申请、单药1L 治疗TNBC 以及单药2L+治疗HR+/HER2- mBC 均处III 期关键临床阶段，另有4 项适应症被中国国家药监局纳入突破性治疗品种，有望加速获批上市助力商业化放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115145625a2229f99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115145625a2229f99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2503327990","title":"科倫博泰生物-B01月13日主力資金流入6萬元 連續3日加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2503327990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503327990?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 16:17","pubTimestamp":1736756229,"startTime":"0","endTime":"0","summary":"01月13日, 科伦博泰生物-B股价涨1.75%，报收168.30元，成交金额2511万元，换手率0.11%，振幅4.41%，量比1.01。科伦博泰生物-B今日主力资金净流入6万元，连续3日净流入，上一交易日主力净流入20万元，今日环比减少70.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为58.33%，平均涨幅为4.78%。该股近5个交易日下跌0.59%，主力资金累计净流入211万元；近20日主力资金累计净流出706万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113161809a21fde32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113161809a21fde32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2503329097","title":"【券商聚焦】招銀國際削科倫博泰(06990)目標價6.4% 惟看好SKB264在今年8-10億元人民幣的銷售目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2503329097","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503329097?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 15:56","pubTimestamp":1736754973,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指，SKB378是科伦博泰 与和铂医药共同开发的TSLP单抗，现已对外授权给Windward公司。SKB378是长效TSLP单克隆抗体，半衰期长，每6个月给药一次，优于需每4周用药的tezepelumab。2024年11月，SKB378治疗COPD的临床试验申请已提交给CDE。该行看好SKB264在2025年8-10亿元人民币的销售目标，并预计今年SKB264将获批用于二线/三线EGFR-TKI耐药的非小细胞肺癌。该行将公司的目标价调至227.88港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1951302","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745212997776}}}